If you searched “tirzepatide before and after,” you were probably hoping to scroll through dramatic transformation photos or personal testimonials. We don’t publish those, and there’s a reason. dosagepeptide.com is a research-use-only (RUO) dosage reference, not a clinic or a supplement store. Before-and-after galleries are marketing, not evidence — they can’t be verified, they quietly omit the people who saw no change, and they say nothing about dose, duration, or safety. What we can share is the honest version: what controlled clinical studies of tirzepatide actually measured, and over what timeframe.
This page is educational and is not medical advice. Tirzepatide sold for research is not the same thing as an approved prescription medicine, and nothing here should be read as a promise of results.
What the research shows over time
Tirzepatide is a dual GIP/GLP-1 receptor agonist that has been tested in large, industry-sponsored phase 3 randomized controlled trials — the SURPASS program (type 2 diabetes) and the SURMOUNT program (obesity). These are clinical human studies, not preclinical animal work and not anecdote, and that distinction matters when you evaluate any “before and after” claim.
The measured picture unfolds gradually. Trials start at a low dose (2.5 mg weekly) and escalate over roughly 20 weeks, and most gastrointestinal side effects cluster in that early window (Jastreboff et al., 2022). Meaningful changes in the trial endpoints — body weight and HbA1c — accumulate over months, not days. In SURPASS-1, 40 weeks of tirzepatide lowered HbA1c by 1.87–2.07 percentage points versus +0.04 with placebo, alongside 7.0–9.5 kg of weight loss (Rosenstock et al., 2021). In SURMOUNT-1, mean weight change at 72 weeks reached −15.0% to −20.9% across doses versus −3.1% with placebo (Jastreboff et al., 2022). A 3-year extension found the reduction was largely sustained (−12.3% to −19.7%) and that far fewer participants with prediabetes progressed to type 2 diabetes (1.3% vs 13.3%) (Jastreboff et al., 2024).
One trial is especially useful for interpreting “after” photos: SURMOUNT-4 used a withdrawal design. People who stopped tirzepatide regained weight (+14.0% over the following year) while those who continued lost a further 5.5% (Aronne et al., 2024). In other words, the measured effect depended on ongoing treatment — a single “after” snapshot doesn’t capture what happens next.
| Study (author, year) | Duration | Population | Measured outcome |
|---|---|---|---|
| SURPASS-1 (Rosenstock et al., 2021) | 40 weeks | Type 2 diabetes | HbA1c −1.87 to −2.07%; weight −7.0 to −9.5 kg |
| SURPASS-5 (Dahl et al., 2022) | 40 weeks | T2D on insulin glargine | HbA1c −2.11 to −2.40%; weight −5.4 to −8.8 kg |
| SURMOUNT-1 (Jastreboff et al., 2022) | 72 weeks | Obesity, no diabetes | Weight −15.0% to −20.9% |
| SURMOUNT-4 (Aronne et al., 2024) | 88 weeks (withdrawal) | Obesity | Continue −5.5% vs stop +14.0% regain |
| SURMOUNT-1, 3-year (Jastreboff et al., 2024) | 176 weeks | Obesity + prediabetes | Weight −12.3% to −19.7%; diabetes onset 1.3% vs 13.3% |
A review of the full SURPASS 1–5 program summarized HbA1c reductions of 1.24–2.58% and weight loss of 5.4–11.7 kg — figures the authors described as unusually large for a single agent (Nauck & D’Alessio, 2022).
Realistic expectations
What the data supports: over many months, at studied doses, tirzepatide produced measurable, dose-dependent reductions in body weight and HbA1c in the trial populations, and continued dosing was needed to maintain them. What the data does not support is any specific “you will look like this” outcome. Trial averages hide wide individual variation — some participants lost far more than the mean and some far less, and every study also included people who discontinued.
This is exactly why online before-and-after photos are unreliable for a research compound. They are self-selected (almost nobody posts a non-result), unverifiable (no dose, purity, timeline, or confirmation the substance was even tirzepatide), and confounded by diet, lifestyle, photography, and sometimes other medications. Trials that used pharmaceutical-grade drug under medical supervision are not a valid stand-in for unregulated research material of unknown identity and purity.
Safety & legal status
Across the trials, the most common adverse events were gastrointestinal — nausea, diarrhea, vomiting, and constipation — mostly mild to moderate and concentrated during dose escalation (Rosenstock et al., 2021; Nauck & D’Alessio, 2022). A meta-analysis across the clinical program did not find an increased risk of major adverse cardiovascular events, though event numbers were low and a dedicated cardiovascular outcomes trial was designed to answer that question more definitively (Nauck & D’Alessio, 2022). Detailed serious-risk information belongs in the prescribing documentation for the approved medicines and is outside the scope of this reference.
Legally and practically: the tirzepatide referenced on this site is for research use only. It is not sold, and must not be used, as a treatment, a weight-loss product, or a human therapeutic. Approved tirzepatide medicines do exist, but they are prescription products dispensed and monitored by licensed clinicians — that is a different thing from research-grade material. If you are considering tirzepatide for a health reason, that is a conversation for a qualified healthcare professional, not a decision to make from photos.
Dosage reference
If you’re here for the figures used in the literature and for reconstitution math, use our reference tools rather than anecdote. See the Tirzepatide dosage chart for vial-based reference numbers, and the peptide dosage calculator to work through reconstitution and injection volume. These are provided for research reference only and are not dosing instructions for human use.
FAQ
Are there real tirzepatide before/after photos?
We don’t publish them. Individual photos can’t be verified and don’t establish what a research compound does. The trustworthy “before and after” is the measured, published trial data above, which reports averages, ranges, and dropouts instead of curated images.
How long until changes appeared in the studies?
Slowly, over months. Dosing began low and escalated over about 20 weeks, with weight and HbA1c endpoints measured at 40 weeks (SURPASS) and 72 weeks or longer (SURMOUNT) (Rosenstock et al., 2021; Jastreboff et al., 2022). There is no credible overnight change anywhere in the data.
Do the measured results last if you stop?
In the one withdrawal trial, people who stopped regained a substantial portion of lost weight over the next year, while those who continued maintained or extended their reduction (Aronne et al., 2024). The measured effect tracked ongoing treatment.
